A Single-arm, Single-center, Prospective Study of Modified DEP Regimens (Doxorubicin+ Etoposide + Methylprednisolone) for the Treatment of Hemophagocytic Lymphohistiocytosis.

A clinical trial, NCT06504030, is currently underway at The First Affiliated Hospital of Soochow University to evaluate the effectiveness and safety of a modified DEP regimen for the treatment of hemophagocytic lymphohistiocytosis (HLH). The trial aims to enroll 20 participants who meet the diagnosis criteria for HLH and are between the ages of 1 and 70. The treatment involves a combination of drugs, including doxorubicin, etoposide, and methylprednisolone, along with other medications depending on the type of HLH. The trial is in the interventional phase and is open to individuals of all genders who provide informed consent. [Extracted from the article]